Non-small cell lung cancer
This article was originally published in The Gray Sheet
Executive Summary
Integrated PET and CT improves diagnostic capability of staging non-small cell lung cancer, according to a study in the June 19 New England Journal of Medicine. Using GE Medical System's Discovery LS integrated PET-CT, the investigators prospectively evaluated 50 patients with proven NSC compared with CT and PET alone and visually correlated PT and CT images. Discovery LS provided additional information in 20 of 49 patients (41%) beyond conventional visual correlation of PET and CT...
You may also be interested in...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.